Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-100245
Filing Date
2024-11-19
Accepted
2024-11-19 17:16:54
Documents
5
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 QUARTERLY REPORT ea0220613-10q_cero.htm 10-Q 642914
2 CERTIFICATION ea0220613ex31-1_cero.htm EX-31.1 10789
3 CERTIFICATION ea0220613ex31-2_cero.htm EX-31.2 9985
4 CERTIFICATION ea0220613ex32-1_cero.htm EX-32.1 4494
5 CERTIFICATION ea0220613ex32-2_cero.htm EX-32.2 4840
  Complete submission text file 0001213900-24-100245.txt   674242
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40877 | Film No.: 241477306
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)